NeOnc Technologies Holdings, Inc. Overview
Industry: Biotechnology: Pharmaceutical Preparations
Sector: Health Care
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100 and NEO212 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO drug development platfor Read More
Newly listed company coverage
Verified company profile, price history, and SEC registration source are available.
10-Q/10-K financial data, or the foreign-issuer equivalent, is not available yet.
Review the SEC registration filingReported Results
No latest earnings report cached yet
Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.
Recent News
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Annual 10-K/20-F financial statement data is not available yet.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.